JP Patent

JP2017537899A — 癌を処置する方法

Assigned to Eisai R&D Management Co Ltd · Expires 2017-12-21 · 8y expired

What this patent protects

本発明は、ヒトヒストンメチルトランスフェラーゼＥＺＨ２の阻害剤を含む医薬組成物、およびＥＺＨ２阻害剤を用いた癌療法に関する。

USPTO Abstract

本発明は、ヒトヒストンメチルトランスフェラーゼＥＺＨ２の阻害剤を含む医薬組成物、およびＥＺＨ２阻害剤を用いた癌療法に関する。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: JP2017537899A
Jurisdiction: JP
Classification: —
Expires: 2017-12-21
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.